Sumanta K. Pal

2010–2025 年に発表

265: 論文数
27,694: 被引用数
89: h 指数
249: i10 指数

被引用数

引用元

国・地域

0%24%その他 24.3%

機関

分野

トピック

全論文

並び替え

検索で開く

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
著者: Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, Marice Alcantara, Tanya B. Dorff, Yung Lyou, Paul Frankel, Yujie Cui, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep Büşra Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Ramya Muddasani, John D. Gillece, Lauren Reining, J.M. Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Sarah K. Highlander, Sumanta K. Pal - Nature Medicine 2022 被引用: 473
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
著者: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 被引用: 1,250
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
著者: Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke, Ari David Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel A. Vaena, Marc‐Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta K. Pal, Chikara Οhyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D. Galsky - The Lancet Oncology 2017 被引用: 1,744
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
著者: Robert J. Motzer, Paul B. Robbins, Thomas Powles, Laurence Albigès, John B.A.G. Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A. Ching, Motohide Uemura, Sumanta K. Pal, B. Yа. Alekseev, Gwénaëlle Gravis, Matthew T. Campbell, Konstantin Penkov, Jae‐Lyun Lee, Subramanian Hariharan, Xiao Wang, Weidong Zhang, Jing Wang, Aleksander Chudnovsky, Alessandra di Pietro, Amber C. Donahue, Toni K. Choueiri - Nature Medicine 2020 被引用: 522
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
著者: Sumanta K. Pal, Ben Tran, John B.A.G. Haanen, Michael E. Hurwitz, Adrian G. Sacher, Nizar M. Tannir, Lihua E. Budde, Simon J. Harrison, Sebastian Klobuch, Sagar S. Patel, Luís Meza, Mary‐Lee Dequéant, Anna Ma, Qiuling Ally He, Leah M. Williams, Alissa Keegan, Ellen B. Gurary, Henia Dar, Sushant Karnik, Changan Guo, Heidi Heath, Rachel R. Yuen, Phuong K. Morrow, Neeraj Agarwal, Samer A. Srour - Cancer Discovery 2024 被引用: 139
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
著者: Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri - The Lancet 2023 被引用: 198
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 被引用: 939
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
著者: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 被引用: 230
Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors
著者: Nicholas Salgia, Paulo Gustavo Bergerot, Manuel Caitano Maia, Nazlı Dizman, Joann Hsu, John D. Gillece, Megan Folkerts, Lauren Reining, Jeffrey M. Trent, Sarah K. Highlander, Sumanta K. Pal - European Urology 2020 被引用: 192
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
著者: Toni K. Choueiri, Robert J. Motzer, Brian I. Rini, John B.A.G. Haanen, Matthew T. Campbell, B. Venugopal, Christian Kollmannsberger, Gwénaëlle Gravis, Mamoru Uemura, J.L. Lee, Marc‐Oliver Grimm, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Sumanta K. Pal, J. Wang, Mariangela Mariani, S. Krishnaswami, Paul Cislo, A. Chudnovsky, Camilla Fowst, Bo Huang, Alessandra di Pietro, Laurence Albigès - Annals of Oncology 2020 被引用: 461
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
著者: Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam S. Chang, Tracy M. Downs, Jason A. Efstathiou, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman‐Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Jonathan D. Tward, Jonathan L. Wright, Lisa A. Gurski, Alyse Johnson-Chilla - Journal of the National Comprehensive Cancer Network 2020 被引用: 628
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
著者: Sumanta K. Pal, Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng, Brian Shuch, Mark N. Stein, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran, Vivek Narayan, Georg A. Bjarnason, Ulka N. Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Melissa Plets, John Wright, Primo N. Lara - The Lancet 2021 被引用: 279
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
著者: Shaan Dudani, Guillermo de Velasco, J. Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Aaron R. Hansen, Georg A. Bjarnason, Benoit Beuselinck, Sumanta K. Pal, Takeshi Yuasa, Nils Kroeger, Ravindran Kanesvaran, M. Neil Reaume, Christina Canil, Toni K. Choueiri, Daniel Y.C. Heng - JAMA Network Open 2021 被引用: 299
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
著者: Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez‐Kozlova, Kevin Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Cetnar, Brock O Neil, Anishka D'souza, Ronac Mamtani, Christos E. Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim‐Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John P. Sfakianos, Sumanta K. Pal - Nature Medicine 2023 被引用: 133
Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study
著者: Saro H. Armenian, Lanfang Xu, Bonnie Ky, Can‐Lan Sun, Leonardo Farol, Sumanta K. Pal, Pamela S. Douglas, Smita Bhatia, Chun Chao - Journal of Clinical Oncology 2016 被引用: 544
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
著者: Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, Jasnoor Malhotra, Xiaochen Li, Tanya B. Dorff, Paul Frankel, Marian Llamas-Quitiquit, Joann Hsu, Zeynep Büşra Zengin, Marice Alcantara, Daniela V. Castro, Benjamin Mercier, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Regina Barragán-Carrillo, Salvador Jaime‐Casas, Ameish Govindarajan, John D. Gillece, Jeffrey M. Trent, Peter P. Lee, Thomas P. Parks, Motomichi Takahashi, Atsushi Hayashi, Marcin Kortylewski, J. Gregory Caporaso, Keehoon Lee, Abhishek Tripathi, Sumanta K. Pal - Nature Medicine 2024 被引用: 82
Melanoma and microbiota: Current understanding and future directions
著者: Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin J. Blaser, Allyson L. Byrd, Nathalie Corvaı̈a, Kasey L. Couts, Diwakar Davar, Lisa Derosa, Howard C. Hang, Geke A.P. Hospers, Morten L. Isaksen, Guido Kroemer, Florent Malard, Kathy D. McCoy, Marlies Meisel, Sumanta K. Pal, Ze’ev A. Ronai, Eran Segal, Gregory D. Sepich‐Poore, Fyza Y. Shaikh, Randy F. Sweis, Giorgio Trinchieri, Marcel R.M. van den Brink, Rinse K. Weersma, Katrine Whiteson, Liping Zhao, Jennifer L. McQuade, Hassane M. Zarour, Laurence Zitvogel - Cancer Cell 2023 被引用: 78
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
著者: Tanya B. Dorff, M. Suzette Blanchard, Lauren Adkins, Laura Luebbert, Neena A. Leggett, Stephanie N. Shishido, Alan Macias, Marissa Morales Del Real, Gaurav Dhapola, Colt A. Egelston, John P. Murad, Reginaldo Cruz Alves Rosa, Jinny Paul, Ammar Chaudhry, Hripsime Martirosyan, Ethan Gerdts, Jamie R. Wagner, Tracey Stiller, Dileshni Tilakawardane, Sumanta K. Pal, Catalina Martínez, Robert E. Reiter, Lihua E. Budde, Massimo D’Apuzzo, Peter Kühn, Lior Pachter, Stephen J. Forman, Saul J. Priceman - Nature Medicine 2024 被引用: 116
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
著者: Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin - Journal of Clinical Oncology 2017 被引用: 508
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
著者: Christopher J.D. Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta K. Pal, Zachary Klaassen - JAMA Oncology 2019 被引用: 302
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
著者: Brian I. Rini, Sumanta K. Pal, Bernard Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott - The Lancet Oncology 2019 被引用: 257
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
著者: Sumanta K. Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal - Journal of Clinical Oncology 2021 被引用: 140
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
著者: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean‐Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jerónimo Rafael Rodríguez‐Cid, Sumanta K. Pal, André M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini - Clinical Cancer Research 2020 被引用: 242
The Microbiome and Genitourinary Cancer: A Collaborative Review
著者: Mark C. Markowski, Stephen A. Boorjian, Jeremy P. Burton, Noah M. Hahn, Molly A. Ingersoll, Saman Maleki Vareki, Sumanta K. Pal, Karen S. Sfanos - European Urology 2019 被引用: 176